Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
The last earnings update was 43 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Homology Medicines. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Homology Medicines's earnings available for a low price, and how does
this compare to other companies in the same industry?
Homology Medicines is not considered high growth as it is expected to be loss making for the next 1-3 years.
Homology Medicines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Homology Medicines's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Homology Medicines's finances.
The net worth of a company is the difference between its assets and liabilities.
Homology Medicines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Homology Medicines's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Homology Medicines's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Homology Medicines has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Arthur O. Tzianabos, Ph.D., has been the Chief Executive Officer, President and Director of Homology Medicines, Inc. since April 2016. Dr. Tzianabos served as the President and Chief Scientific Officer at OvaScience, Inc. from September of 2013 to March of 2016. Dr. Tzianabos served as the Chief Scientific Officer of OvaScience, Inc. from July 2013 to March 31, 2016. Dr. Tzianabos served as Vice President of Program Management, Head of Research and Early Development and Senior Vice President at Shire plc. He has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire's acquisition of Transkaryotic Therapies, Inc. in 2005. Dr. Tzianabos joined Shire in 2005 as Senior Director, Discovery Research and was instrumental in establishing the Discovery Research group and played a leading role in the expansion of Shire HGT research pipeline shortly after the acquisition of TKT by Shire. He serves as Chair of Scientific Advisory Board at OvaScience, Inc. He has been a Member of Scientific Advisory Board at Agilis Biotherapeutics, LLC since June 2014 and as its Director since September 2015. He served as Director of ArmaGen Technologies, Inc. since December 2012. He served as a Director of bluebird bio. Prior to Shire, Dr. Tzianabos served as an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a Consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. He has been a Director of BIND Therapeutics, Inc. since October 2015. He served as a Director of DNIB Unwind, Inc. since October 2015. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease. He holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.
Arthur's compensation has increased whilst company is loss making.
Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Homology Medicines management team is about average.
Chief Technical Operations Officer
Chief Scientific Officer
Co-Founder & Chair of Scientific Advisory Board
CFO, Treasurer & Secretary
Chief Operating Officer
Senior Vice President of Corporate Communications & Patient Advocacy
Director of Corporate Communications
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Homology Medicines board of directors is less than 3 years, this suggests a new board.
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.